UK-based PCR Biosystems issued a statement 1 April saying they are continuing to scale up operations to ensure the critical enzyme mix for COVID-19 tests remain available to the UK and global healthcare systems as demand for testing rises.
\nTo meet current and upcoming requirements and ensure supply chain security, PCR Biosystems has already significantly increased \u2013 and will continue to increase \u2013 manufacture of qPCRBIO Probe 1-Step Go and all other critical reagents for rapid and sensitive RT-qPCR, the company said.
\nThe company noted it has capacity to manufacture enough reagent daily for 4 million reactions \u2013 which is sufficient for millions of diagnostic tests.
\nqPCRBIO Probe 1-Step Go is a universal probe kit designed for fast and sensitive probe-based RT-qPCR. It is PCR Biosystems\u2019s recommended product for COVID-19 diagnostic tests, supporting the detection, quantification and typing of the SARS-CoV-2 virus. All that\u2019s required is the addition of specific primers and probes, together with the swab extract and water. qPCRBIO Probe 1-Step Go is compatible with all qPCR instruments and is engineered for use on a wide range of probe technologies including TaqMan\u00ae, Scorpions\u00ae and molecular beacon probes. In March 2020, PCR Biosystems introduced bulk pack sizes of this key product, to further support customers in high-throughput COVID-19 testing.
\nAlex Wilson, Co-Founder of PCR Biosystems, explained: \u201cThese are unprecedented times, and, as a global PCR company, we are ideally placed to support the scientific and healthcare communities in their response to COVID-19. When the enormity of COVID-19 testing requirements became apparent, we immediately started scaling up production of the critical components. We already have capacity to supply 4 million reactions\u2019 worth of reagent every day \u2013 and we have the option to scale up further if needed to ensure we can always meet global demand.\u201d
\nFor more information on PCR Biosystems\u2019s reagents, visit: www.pcrbio.com<\/p>\n","protected":false},"excerpt":{"rendered":"
UK-based PCR Biosystems issued a statement 1 April saying they are continuing to scale up operations to ensure the critical enzyme mix for COVID-19 tests remain available to the UK and global healthcare systems as demand for testing rises. To meet current and upcoming requirements and ensure supply chain security, PCR Biosystems has already significantly […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[36,35],"tags":[],"class_list":["post-698","post","type-post","status-publish","format-standard","hentry","category-corona-news","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/698"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=698"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/698\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}